E-Novia Logo

E-Novia

E9IA | XMIL

Overview

Corporate Details

ISIN(s):
IT0005391229
LEI:
815600080AB1FC472040
Country:
Italy
Address:
VIA SAN MARTINO, 12, 20122 MILANO
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

E-Novia is a deep-tech 'enterprises factory' that transforms innovative ideas into scalable companies. Specializing in Physical AI, the company designs and develops intelligent solutions that interact with the physical world through robotics, sensors, and embedded systems. Its integrated model covers the entire innovation lifecycle, from market research and engineering to venture building and scaling support. E-Novia has launched a portfolio of ventures in high-growth sectors, including sustainable mobility, autonomous logistics, industrial automation, and wearable haptic technologies.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for E-Novia. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-05 21:09
Capital/Financing Update
APPROVAZIONE DELLE MODIFICHE DEL REGOLAMENTO DEL PRESTITO OBBLIGAZIONARIO DENOM…
Italian 292.3 KB
2025-08-01 12:31
Registration Form
ISCRIZIONE NEL REGISTRO DELLE IMPRESE DEL PROGETTO DI FUSIONE PER INCORPORAZION…
Italian 250.2 KB
2025-07-31 08:05
M&A Activity
DEPOSITO PROGETTO DI FUSIONE PER INCORPORAZIONE DI ESION S.R.L., EXISTO S.R.L. …
Italian 276.5 KB
2025-07-28 19:38
Regulatory News Service
IL GRUPPO E-NOVIA SEMPLIFICA LA STRUTTURA SOCIETARIA: FUSIONE PER INCORPORAZION…
Italian 284.7 KB
2025-07-28 19:35
Board/Management Information
NOMINATO VITTORIO AVOGADRO DI COLLOBIANO COME NUOVO CONSIGLIERE
Italian 259.5 KB
2025-07-12 10:16
Pre-Annual General Meeting Information
Pubblicato l'Avviso di Convocazione dell'Assemblea Ordinaria degli Azionisti
Italian 293.8 KB
2025-07-10 20:37
Pre-Annual General Meeting Information
CONVOCAZIONE DELL’ASSEMBLEA ORDINARIA DEGLI AZIONISTI
Italian 244.6 KB
2025-06-30 18:34
Post-Annual General Meeting Information
E-NOVIA: L’ASSEMBLEA ORDINARIA DEGLI AZIONISTI APPROVA IL BILANCIO AL 31 DICEMB…
Italian 259.0 KB
2025-06-20 10:48
Pre-Annual General Meeting Information
AVVISO DI CORTESIA RELATIVO ALL’ASSEMBLEA DEGLI AZIONISTI
Italian 242.1 KB
2025-06-12 21:33
Audit Report / Information
RELAZIONE DELLA SOCIETA’ DI REVISIONE SUL BILANCIO DI ESERCIZIO E SUL BILANCIO …
Italian 1.8 MB
2025-06-12 21:32
Pre-Annual General Meeting Information
PUBBLICATO L’AVVISO DI CONVOCAZIONE DELL’ASSEMBLEA ORDINARIA DEGLI AZIONISTI
Italian 292.2 KB
2025-06-04 23:16
Earnings Release
IL CONSIGLIO DI AMMINISTRAZIONE APPROVA IL BILANCIO CONSOLIDATO E IL PROGETTO D…
Italian 403.9 KB
2025-05-27 22:49
Report Publication Announcement
VARIAZIONE DEL CALENDARIO EVENTI SOCIETARI 2025
Italian 193.4 KB
2025-03-26 18:55
Capital/Financing Update
Integrale Sottoscrizione del "Prestito Obbligazionario Prededucibile Convertend…
Italian 282.6 KB
2025-03-18 12:04
Board/Management Information
NOMINATO PER COOPTAZIONE NUOVO CONSIGLIERE E DIMISSIONI MEMBRO DEL COMITATO END…
Italian 191.0 KB

Automate Your Workflow. Get a real-time feed of all E-Novia filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for E-Novia via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
THERACRYF PLC Logo
Developing sulforaphane-based therapeutics for oncology and behavioural brain disorders.
United Kingdom TCF
Theranexus Logo
Biopharma developing drug candidates for rare neurological diseases like Batten disease.
France ALTHX
TME Pharma N.V. Logo
Clinical-stage biotech developing TME-targeting therapies for aggressive cancers.
Germany ALTME
Toleranzia AB Logo
Developing immune therapies for rare autoimmune diseases like myasthenia gravis.
Sweden TOL
Transgene Logo
Clinical-stage biotech using viral vectors for cancer vaccines and oncolytic viruses.
France TNG
Tvardi Therapeutics Inc. Logo United States of America TVRD
UCAR Logo
A nonprofit consortium managing atmospheric research and providing resources to the scientific community.
France ALUCR
Hong Kong N/A
Urteste S.A. Logo
Developing non-invasive urine tests for early detection & monitoring of multiple cancers.
Poland URT
VALIRX PLC Logo
Developing early-stage therapeutics & diagnostics for oncology and women's health.
United Kingdom VAL